Aqneursa access in India: the CDSCO named-patient pathway
How patients in the Republic of India legally obtain Aqneursa (levacetylleucine) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Aqneursa in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in India access Aqneursa (levacetylleucine) for neurologic manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients weighing 15 kg or more through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Aqneursa reaches patients in India
Aqneursa (levacetylleucine, an oral modified amino-acid derivative from IntraBio / Zevra Therapeutics, FDA-approved 24 September 2024 for neurologic manifestations of Niemann-Pick disease type C in adult and paediatric patients weighing 15 kg or more, label resource at accessdata.fda.gov) is not visible on the Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in as of 2026-06-01. Indian families access the medicine under the Permission to Import Small Quantities of New Drug for Personal Use, the statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945 read with the New Drugs and Clinical Trials Rules 2019, pathway page at cdsco.gov.in/Drugs-for-Personal-Use. The application is filed online through the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. We give you a written timeline estimate for your case before you commit. Where a hospital is the importer-of-record for an admitted named patient, the parallel Import Licence for Personal Use in CT Form-16 under the Second Schedule and Table-1 of the New Drugs and Clinical Trials Rules 2019 applies, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. The application requires a registered medical practitioner's prescription with National Medical Commission registration number, drug strength and quantity, the patient's NPC1 or NPC2 genetic confirmation, and a treating physician's case summary.
Where Aqneursa is dispensed in India
Aqneursa is an oral powder reconstituted in liquid and administered three times daily; dispensing routes through paediatric neurology, adult neurology, and clinical genetics services with lysosomal storage disorder experience, baseline scoring (SARA, mFARS, or clinical NPC severity scales), and structured longitudinal assessment. Indian Centres of Excellence under the National Policy for Rare Diseases 2021, identified in the policy document at mohfw.gov.in NPRD 2021, host the most-frequent paediatric and adult NPC case load.
What Aqneursa costs in India
Medicine price: quote on request. Every case gets a written custom quote before you commit. Cost layers stacked on the drug cost include international ambient freight (Aqneursa is a stable oral solid that does not require refrigeration per the FDA label), CDSCO permit and customs processing, the dispensing facility's drug-handling fee, and the Reserve Meds coordination fee itemised separately on every firm quote. Goods and Services Tax on life-saving medicines sits at 5 percent. Reconstitution at the point of dose, the three-times-daily schedule, and weight-banded sachet selection are operational planning considerations the dispensing pharmacy handles at family training.
Funding and access barriers for Aqneursa in India
Indefinite three-times-daily Aqneursa dosing on an open-ended basis does not naturally fit the one-time-treatment ceiling. Medicine price: quote on request. You get a written quote for your case before you commit. private health insurers assess unregistered named-patient imports case by case; IRDAI has not issued a uniform rule for this category. The dominant funding pattern is family self-pay, often supplemented by diaspora remittance, crowdfunding through Ketto, Milaap, and ImpactGuru, and the Zevra Therapeutics or IntraBio compassionate-access mechanisms where the manufacturer operates one. Indian patient organisations including the Lysosomal Storage Disorders Support Society (LSDSS) provide structured family support and have engaged with the central rare-disease policy framework.
Recent regulatory and access news for Aqneursa
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a levacetylleucine-specific notification over the last 12 months as of 2026-06-01. The Ministry of Health and Family Welfare continues quarterly Health Minister's Committee updates on the NPRD 2021 Centres of Excellence and disease coverage at mohfw.gov.in; no NPC-specific reclassification altering Aqneursa eligibility has been observed in the most recent published roster. On the manufacturer side, Zevra Therapeutics and IntraBio have continued regional rollout of Aqneursa through 2025 and 2026 disclosures, with EMA review continuing in parallel via the European Medicines Agency human medicines portal at ema.europa.eu. India-specific Aqneursa registration filings have not appeared on the SUGAM approved-product search at cdscoonline.gov.in as of the snapshot date.
Where Reserve Meds fits in Aqneursa cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Aqneursa specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Aqneursa case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Aqneursa is the second FDA-approved targeted therapy for NPC neurologic manifestations; named-patient files document the NPC1 or NPC2 genetic confirmation and current clinical assessment. Indian specialty referral concentrates these cases at the major academic medical centres and oncology networks.
Next step
If your Indian physician has prescribed Aqneursa and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.